In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

Viking Therapeutics reported promising early results for its experimental obesity pill, with increased weight loss at higher ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

When AstraZeneca announced it had licensed the experimental, once-daily obesity pill from Eccogene a year ago for up to $2 ...

Viking Therapeutics Inc.’s stock was up up as much as 3.8% early Friday as excitement continued to build about data on the ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004 ...

Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...

Viking Therapeutics Inc. (VKTX) on Sunday issued positive early results in the trial of its experimental obesity pill VK2735, reports ...